AURLUMYN (Iloprost) Patent Expiration, LOE Window & CMS Spending

AURLUMYN (Iloprost) by Btg International: FDA Orange Book core substance LOE 2041-08-06 (last listed 2044-07-18), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $5,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBtg International
FDA Application & PathwayN217933 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-08-06
Last Listed Patent or Exclusivity Date2044-07-18
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($5,500 intro WAC)